Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 5/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | MMP16 | P51512 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | PARL | Q9H300 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10326376 | 1.00 | HSD17B2 (0.44) | HSD17B2BRD4PTGS2MMP1MMP2 | |
| SCHEMBL10326648 | 1.00 | HSD17B2 (0.44) | HSD17B2BRD4PTGS2MMP1MMP2 | |
| SCHEMBL10326158 | 0.91 | TACR1 (0.39) | HSD17B2 | |
| SCHEMBL10326159 | 0.91 | TACR1 (0.39) | HSD17B2 | |
| SCHEMBL10327102 | 0.91 | TACR1 (0.39) | HSD17B2 | |
| SCHEMBL10326716 | 0.89 | HSD17B2 (0.40) | HSD17B2BRD4MMP1MMP2MMP3 | |
| SCHEMBL10326735 | 0.89 | HSD17B2 (0.40) | HSD17B2BRD4MMP1MMP2MMP3 | |
| SCHEMBL10326715 | 0.89 | HSD17B2 (0.40) | HSD17B2BRD4MMP1MMP2MMP3 | |
| SCHEMBL10326375 | 0.87 | HSD17B2 (0.47) | HSD17B2BRD4 | |
| SCHEMBL10326714 | 0.87 | HSD17B2 (0.47) | HSD17B2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | HSD17B2 1447/4885BRD4 4295/4885PTGS2 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.